Using Canada as a case study, this article argues that regulating biotechnology and nanotechnology is made unnecessarily complex and inherently unstable because of a failure to consult the public early and of-ten enough. Furthermore, it is argued that future regulators (and promoters) of nanotechnology may learn valuable lessons from the mistakes made in regulating biotechnology.
No takes yet. Share an insight, caveat, or question.
A 2004 study studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: